Page 53 - Read Online

Sawhney et al. J Cancer Metastasis Treat 2021;7:48 https://dx.doi.org/10.20517/2394-4722.2021.64 Page 9 of 9

(IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical
Research (GOIRC). J Immunother 2014;37:440-7. DOI PubMed
9. Chamie K, Donin NM, Klöpfer P, et al. Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the
ARISER randomized clinical trial. JAMA Oncol 2017;3:913-20. DOI PubMed PMC
10. Choueiri TK, Kaelin WG Jr. Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat Med 2020;26:1519-30. DOI PubMed
11. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J
Clin Oncol 2005;23:1028-43. DOI PubMed
12. Almeida DV, Oliveira CZ, Soares A, et al; Latin America Cooperative Oncology Group - Genitourinary (LACOG-GU). Meta-analysis
of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor
receptor tyrosine-kinase inhibitors (VEGFR TKIs). J Clin Oncol 2019;37:4579. DOI
13. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med
2007;356:115-24. DOI PubMed
14. Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of
intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and
overall survival update. Eur J Cancer 2018;94:115-25. DOI PubMed PMC
15. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized
phase III trial. J Clin Oncol 2010;28:1061-8. DOI PubMed
16. Hutson TE, Al-Shukri S, Stus VP, et al. Axitinib versus sorafenib in first-line metastatic renal cell carcinoma: overall survival from a
randomized phase III trial. Clin Genitourin Cancer 2017;15:72-6. DOI PubMed
17. Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN
E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016;387:2008-16. DOI PubMed PMC
18. Motzer RJ, Ravaud A, Patard JJ, et al. Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and
updated overall survival results. Eur Urol 2018;73:62-8. DOI PubMed PMC
19. Motzer RJ, Haas NB, Donskov F, et al; PROTECT investigators. Randomized phase III trial of adjuvant pazopanib versus placebo
after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 2017;35:3916-23. DOI PubMed
PMC
20. Gross-Goupil M, Kwon TG, Eto M, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the
phase III, randomized ATLAS trial. Ann Oncol 2018;29:2371-8. DOI PubMed PMC
21. Eisen T, Frangou E, Oza B, et al. Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the
SORCE randomized phase III intergroup trial. J Clin Oncol 2020;38:4064-75. DOI PubMed PMC
22. Gul A, Rini B. Adjuvant therapy in renal cell carcinoma. Cancer 2019;125:2935-44. DOI PubMed
23. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N
Engl J Med 2019;381:1535-46. DOI PubMed
24. Shen M, Chen G, Xie Q, et al. Association between PD-L1 expression and the prognosis and clinicopathologic features of renal cell
carcinoma: a systematic review and meta-analysis. Urol Int 2020;104:533-41. DOI PubMed
25. Choueiri TK, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal
cell carcinoma: randomized, double-blind, phase III KEYNOTE-564 study. J Clin Oncol 2021;39:LBA5. DOI
26. Uzzo R, Bex A, Rini BI, et al. A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC)
patients (pts) at high risk of recurrence following resection (IMmotion010). J Clin Oncol 2017;35:TPS4598. DOI
27. Bex A, Russo P, Tomita Y, et al. A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in
patients with localized renal cell carcinoma at high-risk of relapse after radical or partial nephrectomy (CheckMate 914). J Clin Oncol
2020;38:TPS5099. DOI
28. Renal adjuvant multiple arm randomised trial (RAMPART). Available from: https://clinicaltrials.gov/ct2/show/NCT03288532. [Last
accessed on 7 Jul 2021].
29. Haas NB, Puligandla M, Allaf ME, et al. PROSPER: phase III randomized study comparing perioperative nivolumab versus
observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143). J Clin Oncol
2020;38:TPS5101. DOI
30. S0931, everolimus in treating patients with kidney cancer who have undergone surgery (S0931). Available from:
https://clinicaltrials.gov/ct2/show/NCT01120249 [Last accessed on 7 Jul 2021].
31. Buller DM, Ristau BT. Improving patient selection for adjuvant therapy in high-risk renal cell carcinoma. Ann Transl Med
2019;7:S104. DOI PubMed PMC
32. George DJ, Martini JF, Staehler M, et al. Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma:
exploratory pharmacogenomic analysis. Clin Cancer Res 2019;25:1165-73. DOI PubMed PMC